Appendix:

Transmission model equations

The dynamic transmission model is represented by 10 ordinary differential equations. The mathematical description of our model is described here. In our model, we track the number of individuals to enter the susceptible population who have sex with men (MSM) population \( S \) at a rate of \( \pi \) per year. These individuals enter into the ‘pool’ of MSM, choosing sexual partners from the population. On average they leave the population of those choosing new sexual partners after an average of \( 1/\mu \) years. Thus, out of each compartment we include an outflow rate \( \mu \). The other means by which susceptible individuals can leave this compartment is by becoming HIV-infected. The rate of flow in the number of people who become infected – that is, the force of infection \( (\lambda) \) – is defined below. Then, the rate of change in the total number of susceptible men at time \( t \) is given by

\[
\frac{dS}{dt} = \pi - (\mu + \lambda(t))S(t).
\]

Once an individual has become infected with HIV, he will initially have the status of undiagnosed with primary HIV infection \( (IP) \). Thus, the number of MSM who leave the susceptible population per year, \( \lambda S \), becomes the source for the \( IP \) compartment. There are three ways in which men can leave the undiagnosed primary HIV infection compartment: (i) become diagnosed as HIV-positive (at a rate \( \gamma_P \)), (ii) remain undiagnosed and progress in disease to chronic infection stage (at a rate \( \omega_P \)), or (iii) leave the sexually active population (at rate \( \mu \)). Accordingly, the rate of change in the total number of undiagnosed HIV-positive men in primary infection at time \( t \) is given by

\[
\frac{dI_P}{dt} = \lambda(t)S(t) - I_P(t)(\mu + \gamma_P + \omega_P).
\]

Similarly, the rate of change in the total number of undiagnosed HIV-positive men in chronic and AIDS stage infection at time \( t \) is given by

\[
\frac{dI_C}{dt} = \omega_P I_P(t) - I_C(t)(\mu + \gamma_C + \omega_C + \delta_C)
\]

and

\[
\frac{dI_A}{dt} = \omega_C I_C(t) - I_A(t)(\mu + \gamma_A + \delta_A),
\]

respectively, where the subscripts refer to the different disease stages and people in AIDS stage die of AIDS-related illnesses at a rate \( \delta_A \) (we also include an HIV-related death rate, \( \delta_C \) for people in the chronic stage of HIV infection).

Rates of movement out of compartments of untreated HIV-infected and diagnosed men can be due to (i) disease progression (at rate \( \omega ) \), (ii) commencing antiretroviral therapy (at rate \( \eta ) \), (iii) death (at rate \( \delta ) \), or (iv) leaving the sexually active population (at rate \( \mu ) \). Rates of movement into compartments of untreated HIV-infected and diagnosed men can be due to (i) newly diagnosed as HIV-infected (at rate \( \gamma ) \) or (ii) previously treated men stopping antiretroviral therapy (at rate \( \nu ) \). Then, the rate of change in the total numbers of diagnosed but untreated HIV-positive men in primary, chronic, and AIDS stages of infection at time \( t \) are given by

\[
\frac{dI_P^N}{dt} = \gamma_P I_P(t) - \gamma_P^N I_P^N(t)(\mu + \omega_P + \eta_P),
\]

\[
\frac{dI_C^N}{dt} = \gamma_C I_C(t) + \omega_P I_P^N(t) + \nu_C T_C(t) + \nu_P T_P(t) - I_C^N(t)(\mu + \omega_C + \eta_C + \delta_C),
\]

and

\[
\frac{dI_A^N}{dt} = \gamma_A I_A(t) + \nu_A T_A(t) + \omega_C I_C^N(t) - \gamma_A^N I_A^N(t)(\mu + \eta_A + \delta_A),
\]

where the subscripts refer to the respective disease stages.

Individuals diagnosed with HIV have the option of initiating antiretroviral therapy (ART). Based on the proportion of HIV-infected MSM who are on ART or initiate ART each year we determine the rate of movement from untreated diagnosed compartments to treatment compartments (denoted by \( \eta ) \). The rates of initiating therapy are different for each stage of disease. Individuals on therapy can cease therapy until a later time (due to toxicities etc.), and we define the rate of ceasing treatment as \( \nu \) (individuals treated in primary infection could initiate an early treatment schedule and upon ceasing ART would move into chronic infection (at rate \( \nu_P ) \)). Treatment will delay the progression of disease, but HIV-infected patients on ART can still progress in their infection (at rates \( \tau ) \) and if
in AIDS-stage can still die of AIDS-related illnesses at a slower rate to untreated people (due to ineffective treatment for various possible reasons including drug resistance). Then, the rate of change in the total numbers of treated HIV-positive men in primary, chronic, and AIDS stages of infection at time \( t \) are given by

\[
\frac{dT_p}{dt} = \eta_p I_p^N(t) - T_p(t)(\mu + \nu_p + \tau_p)
\]

\[
\frac{dT_C}{dt} = \eta_C I_C^N + \tau_p T_p(t) + (1 - \rho_A)\eta_A I_A^N(t) - T_C(t)(\mu + \nu_C + \tau_C + \delta_C),
\]

and

\[
\frac{dT_A}{dt} = \rho_A \eta_A I_A^N(t) + \tau_A T_A(t) - T_A(t)(\mu + \nu_A + \delta_T).
\]

Table A1 gives a full description of all of the parameters mentioned above, along with values that were used in the model.

**Force of infection**

The force of infection, \( \lambda \), is the dynamic rate at which susceptible individuals become infected with HIV. This function contains many of the factors that contribute to HIV transmission. Typically \( \lambda \) is calculated as the average number of sexual partners each susceptible person has per year, multiplied by the probability that each new partner is HIV-positive, multiplied by the probability of HIV transmission occurring per partnership per year. Various factors contribute to each of these components.

**Number of sexual partners**

We distinguish between the numbers of casual sexual partners and the numbers of regular partners MSM are likely to have, on average, each year. We let \( c_{ca} \) represent the number of casual partners and \( c_{reg} \) represent the number of casual partners. We use behavioural data\(^1\) on the proportion of men who have 0, 1, 2-10, 11-50, >50 partners to calculate a weighted average at each available time point, to obtain the following trends. We also make the assumption that one partner is regular, on average, and the remaining partners are casual partners.

**Probability that new sexual partner is HIV-positive**

If there was homogeneous non-differential mixing and no change in sexual behaviour between any categories of MSM in our model, then the probability that a new partner is HIV-positive is simply the ratio of the number of HIV-infected men to the total number of men in the population. There is evidence of change in behaviour upon diagnosis and men in AIDS stage disease are likely to have reduced numbers of partners due to their sickness. If healthy undiagnosed and susceptible men have partners per year, then we model the number of partners per year that men with AIDS have as \( \theta_{AIDS} \cdot c \), where \( \theta_{AIDS} \) is a multiplying factor for the reduction in sexual activity due to the effect of illness. We model the number of partners that diagnosed men have per year as \( f \cdot c \). Here, \( f \) refers to the multiplicative increase or decrease in sexual activity; we consider both the possibility of increase or decrease since HIV-positive men may reduce risky sex to avoid infecting others or they may increase risky sex as they are no longer at risk of seroconverting. Thus, the probability of a new partner being HIV-positive is

\[
\frac{I_p + I_C + \theta_{AIDS}I_A + f(I_p^N + I_C^N + \theta_{AIDS}I_A^N) + T_P + T_C + \theta_{AIDS}T_A)}{S + I_p + I_C + \theta_{AIDS}I_A + I_p^N + f(I_C^N + \theta_{AIDS}I_A^N) + T_P + T_C + \theta_{AIDS}T_A}.
\]

Sexual partnerships are likely to be formed irrespective of HIV serology status. A proportion of men will disclose their HIV serostatus to their partner (which is generally reciprocated). We denote the proportion of men who disclose their serostatus to their partner as \( \rho_{\text{disclose}} \). If serostatus is disclosed and a partnership is serodiscordant then we assume that condoms are used in the majority of acts, but if the partnership is thought to be seroconcordant then we assume that condom use will be low. The risk of transmission in the relationships thought to be seroconcordant is due to partners that are undiagnosed but HIV-infected. If serostatus is not disclosed, then we assume that there is average condom use (at the average level reported in survey studies) and that partners of any status/compartment can be chosen.

Serosorting for the formation of partnerships is rare; particularly among HIV-negative MSM (it is more common among HIV-positive MSM) (G. Prestage, pers. comm., National Centre in HIV Epidemiology and Clinical Research). Therefore, we simplify our model by not including serosorting for the establishment of partners. Negotiating condom use based on disclosure of serostatus is relatively common and is an important aspect retained in our model.
Table A1. Definitions, ranges and references for input parameters used in our mathematical model

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
<th>Value</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>( c )</td>
<td>Average number of sexual partnerships per year (undiagnosed MSM)</td>
<td>1–3&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>( \theta_{AIDS} )</td>
<td>Multiplying factor for the reduction in number of sexual partners for men in AIDS stage disease</td>
<td>0.1–0.4</td>
<td></td>
</tr>
<tr>
<td>( p_{anal} )</td>
<td>Percentage of sexual partnerships in which penile-oral intercourse occurs</td>
<td>10–40%</td>
<td>6</td>
</tr>
<tr>
<td>( f )</td>
<td>Multiplying factor for the average change in number of sexual partners post-diagnoses of HIV infection (this reflects a possible range from 50% decrease to 10% increase)</td>
<td>0.4–1.1</td>
<td>6–14</td>
</tr>
<tr>
<td>( p_{disclose} )</td>
<td>Proportion of partnerships in which serostatus is disclosed (in negotiating condom usage)</td>
<td>Regular</td>
<td>0.8–0.9</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td>Casual</td>
<td> </td>
</tr>
<tr>
<td>( p_{condom} )</td>
<td>Proportion of acts in which condoms are used</td>
<td> </td>
<td>1, 4&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>( \varepsilon )</td>
<td>Efficacy of condom protection per act</td>
<td>0.85–0.9</td>
<td>17–21</td>
</tr>
<tr>
<td>( W )</td>
<td>Baseline viral load during chronic infection</td>
<td>( 10^4 )–10&lt;sup&gt;6&lt;/sup&gt; copies/mL</td>
<td>22–26</td>
</tr>
<tr>
<td>( V_p )</td>
<td>Average viral load at primary infection stage</td>
<td>( 10^{4.5} )–10&lt;sup&gt;6&lt;/sup&gt; copies/mL</td>
<td>22–24, 26, 27</td>
</tr>
<tr>
<td>( V_t )</td>
<td>Average viral load at AIDS</td>
<td>( 10^{5.5} )–10&lt;sup&gt;6&lt;/sup&gt; copies/mL</td>
<td>24, 28, 29</td>
</tr>
<tr>
<td>( V_c )</td>
<td>Average viral load in effectively treated individual</td>
<td>10–100 copies/mL</td>
<td>30–32</td>
</tr>
<tr>
<td>( P_c )</td>
<td>Proportion of individuals on antiretroviral therapy (in which viral load is suppressed)</td>
<td> </td>
<td>1, 7, 33, 34&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>( \beta_C, \beta_C^V )</td>
<td>Probability of HIV transmission per act from an individual in chronic stage of infection</td>
<td>0.0015–0.0025</td>
<td>35–40</td>
</tr>
<tr>
<td>( \beta_O, \beta_O^V, \beta_C, \beta_C^V )</td>
<td>Probability of HIV transmission per act from an individual in primary or AIDS stage of infection</td>
<td> </td>
<td>5</td>
</tr>
<tr>
<td>( \beta_T, \beta_T^V )</td>
<td>Probability of HIV transmission per act from a treated individual</td>
<td> </td>
<td>5, 41</td>
</tr>
<tr>
<td>( P_{STI} )</td>
<td>Proportion of HIV-negative MSM who have other STIs</td>
<td>0.05–0.15</td>
<td>42, 43</td>
</tr>
<tr>
<td>( b_{STI} )</td>
<td>The multiplicative increase in transmission probability due to the presence of other STIs</td>
<td>2–5</td>
<td>44–50</td>
</tr>
<tr>
<td>( n_{reg} )</td>
<td>Average number of anal intercourse acts per regular partner per week</td>
<td>1.6–2.4</td>
<td>51</td>
</tr>
<tr>
<td>( n_{cas} )</td>
<td>Average number of anal intercourse acts per casual partner (over duration of casual relationship)</td>
<td>1–2</td>
<td>16, 51</td>
</tr>
<tr>
<td>( P_{Test} )</td>
<td>Proportion of MSM who test for HIV infection each year</td>
<td> </td>
<td>1&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>( 1/\gamma_A )</td>
<td>Average time from the beginning of AIDS before individual is likely to be diagnosed with infection</td>
<td>2–4 months</td>
<td> </td>
</tr>
<tr>
<td>( 1/\omega_p )</td>
<td>Average time for untreated individuals to progress from primary infection to chronic infection</td>
<td>3–9 months</td>
<td>23, 52, 53</td>
</tr>
<tr>
<td>( 1/\omega_c )</td>
<td>Average time for individuals to progress from chronic infection to AIDS</td>
<td>8–12 years</td>
<td>22, 28, 54–57</td>
</tr>
<tr>
<td>( P_p )</td>
<td>Proportion of people diagnosed in primary infection who will commence treatment</td>
<td> </td>
<td> </td>
</tr>
<tr>
<td>( 1/\nu_p )</td>
<td>Average time to cease treatment for individuals with primary infection</td>
<td>6–12 months</td>
<td> </td>
</tr>
<tr>
<td>( P_p^\mu )</td>
<td>Proportion of people who started ART in primary infection and continue ART after finishing dosing schedule</td>
<td>65–75%</td>
<td> </td>
</tr>
<tr>
<td>( P_c )</td>
<td>Proportion of people in chronic infection who will commence treatment</td>
<td>65–75%</td>
<td>1, 4, 58</td>
</tr>
<tr>
<td>( P_d )</td>
<td>Proportion of people with AIDS who commence treatment that experience treatment failure</td>
<td>0–0.1</td>
<td> </td>
</tr>
<tr>
<td>( 1/\eta_d )</td>
<td>Average time before individuals with AIDS commence therapy</td>
<td>1–3 months</td>
<td> </td>
</tr>
<tr>
<td>( 1/\eta_c )</td>
<td>Average time before diagnosed individuals in chronic infection commence therapy</td>
<td>2–10 years</td>
<td> </td>
</tr>
<tr>
<td>( 1/\nu_c )</td>
<td>Average time to cease treatment for individuals with chronic infection</td>
<td>6–12 years</td>
<td>1</td>
</tr>
<tr>
<td>( 1/\nu_A )</td>
<td>Average time to cease treatment for individuals with AIDS</td>
<td>8–14 years</td>
<td>1</td>
</tr>
<tr>
<td>( 1/\mu )</td>
<td>Average time for individuals to ‘retire’ out of sexually active population (no longer obtaining new partners)</td>
<td>30–35 years</td>
<td>56</td>
</tr>
<tr>
<td>( \delta_C )</td>
<td>Proportion of untreated MSM in chronic infection who die each year</td>
<td>1–2%</td>
<td>59–63</td>
</tr>
<tr>
<td>( \delta_C^\mu )</td>
<td>Proportion of treated MSM in chronic infection who die each year</td>
<td>1–2%</td>
<td>59–63</td>
</tr>
<tr>
<td>( 1/\delta_d )</td>
<td>Average time until death from the onset of AIDS for untreated individuals</td>
<td>0.5–1.5 years</td>
<td>63–66</td>
</tr>
<tr>
<td>( 1/\delta_r )</td>
<td>Average time until AIDS-related death for individuals in AIDS stage but on ART (with treatment failure)</td>
<td>0.5–5 years</td>
<td>56, 63, 65, 67–73</td>
</tr>
<tr>
<td>Parameter</td>
<td>Description</td>
<td>Value</td>
<td>Ref.</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>$1/\tau_C$</td>
<td>Average time of disease progression for treated individual with chronic infection to progress to AIDS</td>
<td>$1/\alpha_C &lt; 1/\tau_C &lt; 20$</td>
<td></td>
</tr>
<tr>
<td>$\pi$</td>
<td>Number of new susceptible individuals entering the MSM population per year (this is $\sim 3-3.5%$ of men)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nationally</td>
<td>2000–2500$^b$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NSW</td>
<td>35–40%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VIC</td>
<td>22–27%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>QLD</td>
<td>17–22%</td>
<td></td>
</tr>
</tbody>
</table>

$^a$We evaluated available data from primary infection cohorts on the percentage of HIV-infected MSM who commenced ART within 1 year of HIV diagnosis, including patients recruited to the Acute Infection and Early Disease Research Program (CORE 01) protocol established by the National Institutes of Health, and the Primary HIV and Early Disease Research: Australian Cohort (PHAEDRA) established by the National Centre in HIV Epidemiology and Clinical Research. This data has large uncertainty (summarised in reference 58), is limited in time and only includes NSW and VIC. Sample sizes are also not sufficient (as low as four in some years for VIC and six for NSW). Consequently, this has been used as a rough guide but we make assumptions in the trends in early treatment based on personal communication with clinicians (e.g. Prof. Tony Kelleher (NCHECR and Centre for Immunology at St Vincent’s Hospital, tkelleher@cfl.unsw.edu.au)). We estimate the basic anecdotal trends observed over the past few years, shown in Table 1 of the main text. However, since there are no firm data for the trends, we include greater uncertainty bounds on this time-dependent parameter than on the others (we use a multiplicative uncertainty range on these trends of 0.6–1.2). We also assume that the initial dosing schedule for these patients who commence treatment in primary infection is 6–12 months, after which time 60–70% of these patients will continue ART and the remaining patients will discontinue therapy until a later time.

$^b$This leads to $\sim 150\,000$–$175\,000$ MSM nationally. The proportion of new MSM in NSW, VIC, QLD each year as a subset of the total National number are indicated.

$^c$For each of these time-dependent parameters we include an uncertainty range of $\pm 5\%$.

Our model requires estimates of the proportion of partnerships in which serostatus is disclosed in order to negotiate condom usage, $p_{\text{disclose}}$. We use data on the percentage of men who reported UAI and always disclosed serostatus,$^1$ and we included a $\pm 25\%$ uncertainty on the data.

**Condom use**

In regular relationships that are serodiscordant, we assume that average condom usage is high. Based on the Futures study,$^4$ we assume condoms are used in 75–85% of anal intercourse acts between discordant MSM. However, in regular relationships that are thought to be seroconcordant we assume that average condom usage is relatively low; we assume condoms are used in 5–10% of acts.$^4$ In casual relationships, serological disclosure is not as common as in regular relationships, but if the MSM in a casual relationship determines that they are seroconcordant we assume that average condom usage is relatively low; we assume condoms are used in 5–10% of acts. We assume that condoms are used more frequently in casual partnerships than in regular partnerships; thus, if it is thought that a casual relationship is seroconcordant then $p_{\text{condom}}^{\text{sero}} < p_{\text{condom}}^{\text{cas}} < 10\%$.

**Probability of HIV transmission per discordant partnership per year**

We denote the probability of HIV-transmission from an infected male to an uninfected male during a single unprotected act of anal intercourse by $\beta$. However, if a condom is used as protection during intercourse then the probability of transmission is reduced. If $\varepsilon$ is the efficacy of condoms then the transmission probability per protected act is $(1-\varepsilon)\beta$. We consider the average number of coital acts per partner unit time ($\eta$) and the proportion of these acts in which condoms are used ($p_{\text{condom}}$) to calculate the probability of transmission of infection per partnership over time. If $\beta_{\text{condom}}$ is the probability of HIV-transmission during a single coital act in a discordant partnership with protection type $i$ (condom or no protection), then the probability of remaining uninfected after the single act is $(1-\beta_{\text{condom}})$. Since each discordant coital act results in either transmission of infection or not (two possible outcomes), we have a Bernoulli trial, assuming each act is independent and has equal transmission for each protection option.

Accordingly, the probability of remaining uninfected after all $n$ $p_{\text{condom}}$ and $n(1-p_{\text{condom}})$ discordant sex acts that involved protection or no protection is binomial: $(1-(1-\varepsilon)\beta)^{p_{\text{condom}}}$ and $(1-\beta)^{n(1-p_{\text{condom}})}$, respectively. Thus, together the probability of acquiring infection per discordant partnership per year is given by

$$
\hat{\beta} = 1 - (1 - (1 - \varepsilon)\beta)^{p_{\text{condom}}} (1 - \beta)^n(1-p_{\text{condom}}).
$$

This expression is valid in the case of a standard transmission probability $\beta$. But the presence of other sexually transmissible infections, both ulcerative and non-ulcerative, can increase the transmission of HIV. Therefore, we consider the proportion of men who have other sexually transmissible infections ($p_{\text{STI}}$) and the multiplicative increase in the transmission
probability due to the presence of other infections($b_{\text{STI}}$). Accordingly, the probability of acquiring infection per discordant partner per year is adjusted to become

\[ 1 - (1 - (1 - \varepsilon)\beta')^{n_{\text{condis}}}(1 - \beta')^{n(1 - \beta_{\text{condis}})}, \]

where

\[ \beta' = (1 - p_{\text{STI}})\beta + p_{\text{STI}}b_{\text{STI}}\beta. \]

**Combining factors for the resultant force of infection function**

The force of infection is not as simple as multiplying each of the components together. This is because each compartment of HIV-infected person will have a different transmission probability. Average HIV viral load differs between disease stages and in individuals effectively treated with combination antiretroviral therapy. To calculate the transmission probabilities for each of these compartments we employ the relation described by Quinn et al., namely,

\[ \beta = 2.45^{\log_{10} \nu} \beta_{C}, \]

where \( \nu \) is the average viral load associated with a stage of infection, \( W \) is a baseline viral load taken at chronic infection, and \( \beta \) is the transmission probability for someone in chronic infection. That is, for each \( \log_{10} \) increase in viral load there is a 2.45 times increase in the transmission probability.

Taken together, our expression for the force of infection is given by:

\[
\lambda = c_{\text{reg}} \left[ p_{\text{disclose}}^{\text{reg}} \left( \hat{\beta}_{p}^{\text{reg}} | \text{low condom} \right) l_{p} + \hat{\beta}_{C}^{\text{reg}} | \text{low condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
\[
+ p_{\text{disclose}}^{\text{reg}} f(\hat{\beta}_{p}^{\text{reg}} | \text{high condom} \right) l_{p} + \hat{\beta}_{C}^{\text{reg}} | \text{high condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
\[
+ (1 - p_{\text{disclose}}^{\text{reg}}) f(\hat{\beta}_{p}^{\text{reg}} | \text{ave condom} \right) l_{p} + \hat{\beta}_{C}^{\text{reg}} | \text{ave condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
\[
+ (1 - p_{\text{disclose}}^{\text{reg}}) f(\hat{\beta}_{p}^{\text{reg}} | \text{high condom} \right) l_{p} + \hat{\beta}_{C}^{\text{reg}} | \text{high condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
\[
+ c_{\text{cas}} \left[ p_{\text{disclose}}^{\text{cas}} \left( \hat{\beta}_{p}^{\text{cas}} | \text{low condom} \right) l_{p} + \hat{\beta}_{C}^{\text{cas}} | \text{low condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
\[
+ p_{\text{disclose}}^{\text{cas}} f(\hat{\beta}_{p}^{\text{cas}} | \text{high condom} \right) l_{p} + \hat{\beta}_{C}^{\text{cas}} | \text{high condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
\[
+ (1 - p_{\text{disclose}}^{\text{cas}}) f(\hat{\beta}_{p}^{\text{cas}} | \text{ave condom} \right) l_{p} + \hat{\beta}_{C}^{\text{cas}} | \text{ave condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
\[
+ (1 - p_{\text{disclose}}^{\text{cas}}) f(\hat{\beta}_{p}^{\text{cas}} | \text{high condom} \right) l_{p} + \hat{\beta}_{C}^{\text{cas}} | \text{high condom} \right) c + \theta_{\text{AIDS}} l_{A} + f(\theta_{P}^{N} + \theta_{P}^{C} + \theta_{\text{AIDS}} l_{A} + T_{P} + T_{C} + \theta_{\text{AIDS}} T_{A}) \]
where the $\beta$ parameters are each specified by the transmission probability per partnership per year as defined above and based on the various behavioural and biological parameters (including number of acts for each type of relationship, condom usage, and viral loads affecting the transmission probabilities).

References

4. Grierson J, Thorpe R, Pitts M. HIV Futures 5: Life as we know it, monograph series number 60. 2006, The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia.


A. Hoare et al.


http://www.publish.csiro.au/journals/sh